Biotech IV Monitor

SYRE — Spyre Therapeutics Inc.

$9.0B market cap · 3 upcoming readouts tracked

Clinical trial readout dates for Spyre Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is June 2027.

Next readoutJune 2027in ~7 months
Upcoming readouts3none in Phase 3
Market cap$9.0B
Cash & investments$1.10B~11 quarters at last loss rate
Recent 8-K filings1latest 2026-11-03

Upcoming readouts

Phase 2 SPY001
Ulcerative Colitis; Inflammatory Bowel Diseases · NCT07012395
June 2027
Recruiting
Phase 2 SPY072
Hidradenitis Suppurativa (HS) · NCT07766005
October 2027
Recruiting
Phase 2 SPY001
Ulcerative Colitis; Inflammatory Bowel Diseases · NCT07652294
March 2029
Enrolling

Cash position

Spyre Therapeutics Inc. reported $1.10B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-03). Its net loss for that quarter was $96M; at that rate the cash would last about 11 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-03

Companies working on similar indications

Discussion

No messages yet. If you follow SYRE, you can start the conversation.
Track SYRE in real time
See live implied volatility for SYRE and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on SYRE
Contact — questions or corrections about SYRE: dukeupt@gmail.com